Widad is collaborating with Rinani Dynamic Sdn Bhd to distribute the oral vaccine in Malaysia. It is being developed by US-based biotechnology company Vaxart. KUALA LUMPUR: Widad Group Bhd’s foray into distributing an oral-based (tablet) Covid-19 vaccine developed by Vaxart, Inc moved a step forward after the phase one of the clinical trial achieved positive response. Widad is collaborating with Rinani Dynamic Sdn Bhd to distribute the oral vaccine in Malaysia. It is being developed by US-based biotechnology company Vaxart. Vaxart’s vaccines are designed to be administered using tablets that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. According to the report published by Vaxart on Nasdq, Vaxart Covid-19 oral vaccine was generally well-tolerated, and immunogenic as measured by multiple markers of immune response to the Covid-19 antigens. The report also showed that Vaxart Covid-19 oral vaccine could have broad activity against existing and future coronavirus strains. Widad managing director Datuk Mohd Rizal Mohd Jaafar said these results are timely due to the emergence of new variants less responsive to first generation vaccines. Hence, making potential cross-reactivity another important advantage of next-generation vaccines. “These results, together with recent data from other biotechnology companies that are currently doing their clinical study on the Covid-19 vaccine, further raise our confidence in the success of Vaxart Covid-19 oral vaccine, ” he added.
apple developer account
buy high quality apple developer account, in buyappleacc.com, shop in one step and good satisfying services, buyappleacc.com is a reputed apple developer account seller, working almost 3 years in bussiness.